ArticleFolia microbiologica2026
In Vitro probiotic assessment and optimization of enhanced spore production in submerged fermentation of Bacillus toyonensis OQ071612.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Certain species within the Bacillus genus, such as Bacillus toyonensis, are widely used as commercial probiotics; however, comprehensive screening and safety evaluation remain essential because some Bacillus species, including B. anthracis and B. cereus, are pathogenic and toxin-producing. In the present study, a soil-derived isolate, B. toyonensis OQ071612, exhibited strong inhibitory activity against multiple representative human enteropathogens and was therefore selected for detailed characterization. The strain demonstrated high tolerance to harsh gastrointestinal and processing-related stress conditions, including low pH, simulated gastric fluid, simulated intestinal fluid, bile salts, and elevated temperatures. In addition, B. toyonensis OQ071612 displayed several desirable probiotic attributes, such as antioxidant activity and bile salt hydrolase (BSH) activity, while showing no hemolytic activity and minimal cytotoxicity toward Caco-2 cells. Antibiotic susceptibility testing revealed sensitivity to vancomycin, levofloxacin, sulfamethoxazole, and doxycycline, with intermediate sensitivity to azithromycin and amoxicillin, indicating the absence of acquired antimicrobial resistance associated with mobile genetic elements. Response surface methodology (RSM) was employed to optimize biomass and spore production, achieving optimal conditions at pH 6.5, 40 °C, 150 rpm agitation, and 0.26 vvm aeration, resulting in 2.7-fold and 6.5-fold increases in biomass and spore yields, respectively. Furthermore, supplementation with B. toyonensis OQ071612 significantly enhanced body mass gain in rats, supporting its potential as a probiotic candidate for animal feed and suggesting possible relevance for future human applications. Collectively, these findings demonstrate that B. toyonensis OQ071612 possesses strong probiotic functionality, favorable preclinical safety characteristics, and promising industrial scalability, supporting its potential as a probiotic candidate for animal feed applications and providing a basis for future evaluation in human-related applications.
Indexed as
Identifiers
42096107What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.